Notably, the antitumor effects of the selective COX-2 inhibitor Celecoxib in colon cancer cells are augmented when combined with inhibition of 5-LOX activity with the FLAP inhibitor MK886 [48]. This evidence concerns the gene ALOX5AP and malignant colon neoplasm.